The appeals court for the Federal Circuit upheld a lower court’s ruling, finding that Regeneron has not sufficiently ...

Regeneron and Bayer's efforts to defend their lucrative eye disease therapy Eylea from competition have been boosted by FDA approval of a new high-dose formulation of the drug. The US regulator ...

Regeneron recently announced it would initiate a quarterly dividend of $0.88, a competitive amount for a company first ...

The fund outperformed its benchmark and peers for the final quarter and full year 2024, driven by positive stock selection.

The Eylea franchise -- including a high-dose (HD) formulation that first earned approval in 2023 -- is facing stiff competition, biosimilar and otherwise. The medicine's sales growth has slowed ...

Two one-shot doses of 4D-150 are being tested in the study and compared to Eylea. The high dose of the gene therapy – which is designed to express both aflibercept and an RNA interference (RNAi ...

Alvotech leads in developing EYLEA high dose and Entyvio biosimilars. - Symphony biosimilar approval is expected by year-end, with global reach in early 2025. - Exclusion of HUMIRA from ...

Pipeline Expansion: - Investments in early-stage pipeline include over 15 molecules in development. - Alvotech leads in developing EYLEA high dose and Entyvio biosimilars. - Symphony biosimilar ...

The fund outperformed its benchmark and peers for the final quarter and full year 2024, driven by positive stock selection.